antiretroviral therapy (ART)
Jump to navigation
Jump to search
Indications
- treatment of retroviral infection
- treatment of HIV infection
Procedure
- treatment with antiretroviral agent(s)
Notes
- 3 drugs from 2 different classes
- 2 nucleoside reverse transcriptase inhibitors
- integrase inhibitor[9]
- antiretroviral therapy with 3TC, tenofovir, or both, reduces risk for hepatitis B virus infection ~90% compared with other or no antiretroviral therapy[5]
- all-cause mortality in the 1st year declined from 2000-2003 to 2008-2010 (RR=0.71)[7]
- many HIV patients on antiretroviral therapy will not have viral rebound in their lifetimes[8]
- viral rebound rate 1.0% per year for homosexual men > 45 years of age after 7 years of antiretroviral therapy[8]
More general terms
More specific terms
Additional terms
References
- ↑ The Antiretroviral Therapy (ART) Cohort Collaboration. HIV treatment response and prognosis in Europe and North America in the first decade of highly active retroviral therapy. A collaborative analysis. Lancet 2006, 36:451 PMID: https://www.ncbi.nlm.nih.gov/pubmed/1689083
- ↑ Yilmaz A et al, Cerebrospinal fluid viral loads reach less than 2 copies/mL in HIV-1 infected patients with effective antiretroviral therapy. Antivir Ther 2006, 11:833
Spudich S et al, Treatment benefit on cerebrospinal fluid HIV-1 levels in the settings of systmeic virological suppression and failure. J Infect Dis 2006, 194:1686 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17109340 - ↑ Bartlett JA et al, An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 2006, 20:2051 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17053351
- ↑ Goetz MB Recommendations for Initiating Antiretroviral Therapy Reflect Return to Earlier Treatment Methods http://guideline.gov/expert/expert-commentary.aspx?f=rss&id=37872
- ↑ 5.0 5.1 Gatanaga H et al. Prophylactic effect of antiretroviral therapy on hepatitis B virus infection. Clin Infect Dis 2013 Jun 15; 56:1812. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23487374
- ↑ Greig J, Casas EC, O'Brien DP, Mills EJ, Ford N. Association between older age and adverse outcomes on antiretroviral therapy: a cohort analysis of programme data from nine countries. AIDS. 2012 Jul 31;26 Suppl 1:S31-7. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22781173
- ↑ 7.0 7.1 The Antiretroviral Therapy Cohort Collaboration Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. The Lancet. HIV. 10 May 2017 http://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(17)30066-8/fulltext
- ↑ 8.0 8.1 8.2 O'Connor J et al. Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: An observational cohort study. Lancet HIV 2017 May 4; <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28479492 Free Article <Internet> http://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(17)30053-X/fulltext
- ↑ 9.0 9.1 Medical Knowledge Self Assessment Program (MKSAP) 18, American College of Physicians, Philadelphia 2018